Figure 1.

An overview of targeting IgG2 for COVID-19 vaccine: (A) The structure of SARS-CoV-2 with its proteins is shown on the upper left corner, As S-glycoprotein is a frequent target, the S encoding gene, and the IFN-γ gene inserted in a plasmid, is depicted, as sub-unit vaccine. The expression of these genes leads to the activation of Th1 and B cells, thus IgG2. (B) The adoptive transfer of anti-S IgG2 is shown on the upper right corner, like a needle containing antibodies. The expansion of IgG2 reduces the activation of immune cells like monocytes, neutrophil, eosinophil, and DC, and their cytokine expression. IgG2 also blocks the activation of complement-mediated recruitment of the neutrophils into the lung. All these are attributable to low inflammatory responses and the protection of lung inflammation. The picture is created at https://biorender.com/.